131
Participants
Start Date
September 30, 2010
Primary Completion Date
February 28, 2015
Study Completion Date
April 30, 2015
Everolimus
Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
Sunitinib
50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
Duke Univeristy Medical Center, Durham
SCRI, Nashville
The Vanderbilt Clinic, Henry-Joyce Cancer Center, Nashville
Cleveland Clinic, Cleveland
Indiana University Melvin and Bran Simon Cancer Center, Indianapolis
Karmanos Cancer Institute/Wayne State University, Detroit
University of Chicago, Chicago
Washington Univ in St. Louis-School of Medicine, St Louis
Oregon Health & Science University, Portland
BC Cancer Agency, Vancouver
CancerCare Manitoba, Med Onc, Dept Hem and Onc, Winnipeg
London Health Sciences Center, London
Cambridge Cancer Trials Centre, Cambridge
The Royal Marsden NHS, London
The Christie Hospital NHS, Manchester
Weston Park Hospital, Sheffield
Churchill Hospital, Headington
Beatson West Scotland Cancer Centre, Glasgow
Lead Sponsor
Novartis
INDUSTRY
Pfizer
INDUSTRY
Duke University
OTHER